Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
β<sub>2</sub>-Adrenergic Receptor <i>(ADRB2)</i> Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study.
|
31683975 |
2019 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients.
|
30608978 |
2019 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan.
|
30349222 |
2019 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because β2AR agonists are prescribed mostly for chronic obstructive pulmonary disease (COPD), often caused by long-term nicotine abuse, we analyzed other markers of smoking.
|
31127070 |
2019 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical management of asthma and chronic obstructive pulmonary disease (COPD) has primarily relied on the use of beta 2 adrenergic receptor agonists (bronchodilators) and corticosteroids, and more recently, monoclonal antibody therapies (biologics) targeting specific cytokines and their functions.
|
31379597 |
2019 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These 11 therapies were for patients with heart failure (angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, aldosterone receptor antagonists and digoxin), stable coronary artery disease (intensive statin therapy), asthma exacerbations (early inhaled corticosteroids in the emergency department and anticholinergics), chronic obstructive pulmonary disease (long-acting muscarinic antagonists and long-acting beta-2 adrenoceptor agonists) and schizophrenia (second-generation antipsychotics and depot/maintenance antipsychotics).
|
30045724 |
2018 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that differences in emphysema distribution and heterogeneity may have masked significant alterations of the bronchodilator response among ADRB2 genotypes in COPD patients in previous studies.
|
28964817 |
2018 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data suggested that Arg/Arg homozygosity at codon 16 of the ADRB2 gene predisposes patients to a clinically more severe course of COPD.
|
28093224 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Salmeterol is a long-acting β2-adrenergic receptor agonist used to treat chronic obstructive pulmonary disease.
|
28398147 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggested that the ADRB2 gene polymorphisms may have vital role in COPD risk, severity, and bronchodilator response among Egyptian population.
|
28327457 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of the genotypes and alleles of rs1042711 in ADRB2 showed a significant difference between the COPD and control groups (p < 0.05); compared with the CC genotype, the non-CC genotypes showed an increased COPD risk (p = 0.002).
|
28753063 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells.
|
27927912 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.
|
28868931 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Eighty-two patients with COPD and 17 healthy smokers were recruited and screened for ADRb2 (T164I and R175R), for CHRM2 (rs1824024) and for CHRM3 (-513C/A and -492C/T).
|
26633752 |
2016 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We did a prespecified analysis of the ADRB2 polymorphisms Arg16Gly and Gln27Glu within the 1 year randomised, double-blind, double-dummy, parallel-group Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) trial, comparing the effects of treatment with tiotropium or salmeterol on exacerbations in 7376 patients with COPD.
|
24461901 |
2014 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The exploration of these mechanisms may contribute to the optimization of β2-AR target therapy in chronic obstructive pulmonary disease.
|
24905583 |
2014 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we found that the rare Thr164Ile polymorphism in ADRB2 was associated with reduced lung function and risk of COPD, whereas the more common Gly16Arg and Gln27Glu were not.
|
25186548 |
2014 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the objective of this study was to determine the role of β2ARs in EPCs function and, if this role is altered, in the COPD population.
|
23448263 |
2013 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygous haplotype for the CysGlyGln of β2AR may be associated with susceptibility to desensitization to LABA in patients with COPD.
|
22526864 |
2012 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested the hypothesis that three functional polymorphisms in the ADRB2 gene (Thr164Ile, Gly16Arg and Gln27Glu) are associated with reduced lung function, asthma or chronic obstructive pulmonary disease (COPD).
|
22075484 |
2012 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, a meta analysis was done to investigate the effect of polymorphisms in the β2-adrenergic receptor (ADRB2) gene on the risk of COPD and lung function.
|
22884155 |
2012 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several once-daily β(2)-AR agonists or ultra-long-acting β(2)-AR-agonists (LABAs), such as indacaterol, olodaterol, and vilanterol, are already in the market or under development for the treatment of COPD and asthma, but current recommendations suggest the use of LABAs only in combination with an inhaled corticosteroid.
|
22611179 |
2012 |
Chronic Obstructive Airway Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An increase of the ADRB2 genes expression was demonstrated in patients with severe asthma and COPD as compared with patients with mild and moderate disease.
|
22192964 |
2012 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our analysis showed little evidence for the association between these ADRB2 variants and indacaterol response, suggesting that ADRB2 genetic variation is unlikely to have a major role in differential response to indacaterol treatment in COPD patients.
|
22158330 |
2012 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To examine the association of ADRB2 polymorphisms and preferential BDR to β2-agonists and anticholinergics in patients with COPD.
|
21881540 |
2011 |